Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Melanoma, Cutaneous Malignant × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 42 Neuroblastoma 16 Glioma 15 Brain Neoplasms 13 Astrocytoma 10 Neoplasms 9 Rhabdomyosarcoma 8 Sarcoma, Ewing 7 Recurrence 6 Medulloblastoma 6 Oligodendroglioma 5 Sarcoma 4 Osteosarcoma 4 Melanoma 4 Small Cell Lung Carcinoma 3 Neuroendocrine Tumors 3 Neuroectodermal Tumors, Primitive 3 Lymphoma 3 Gliosarcoma 3 Diffuse Intrinsic Pontine Glioma 3 Wilms Tumor 2 Rhabdoid Tumor 2 Pyloric Stenosis, Hypertrophic 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Hepatoblastoma 2 Ganglioneuroblastoma 2 Fallopian Tube Neoplasms 2 Ependymoma 2 Colorectal Neoplasms 2

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Eye Movement Desensitization Reprocessing 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06743126 2026-04-13

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡